GlobeNewswire by notified

CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS

Share
Bid procedure, 2023-05-26
BondsSWEDEN I/L BOND: 3111. SE0007045745. 2032-06-01

SWEDEN I/L BOND: 3114, SE0013748258, 2030-06-01


Bid date2023-05-26
Bid times09.00-10.00 (CET/CEST) on the Bid date
Offered volume (corresponding nominal amount)3111: 100 million SEK +/-100 million SEK

3114: 150 million SEK +/-150 million SEK


Highest permitted bid volume (corresponding nominal amount)3111: 100 million SEK per bid

3114: 150 million SEK per bid


Lowest permitted bid volume (corresponding nominal amount)SEK 10 million per bid
Expected allocation timeNot later than 10.15 (CET/CEST) on the Bid date
Delivery and payment date2023-05-30
Settlement amountTo be paid to the Riksbank's account in Euroclear Sweden AB's securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK

Stockholm, 2023-05-19

This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Schouw & Co. aktietilbagekøbsprogram, uge 18 20246.5.2024 15:11:08 CEST | pressemeddelelse

Den 4. marts 2024 iværksatte Schouw & Co. et aktietilbagekøbsprogram som beskrevet i selskabsmeddelelse nr. 13 af 1. marts 2024. I henhold til programmet vil Schouw & Co. i perioden fra 4. marts 2024 til 31. december 2024 købe egne aktier for et maksimalt beløb på 200 mio. kr. Aktietilbagekøbsprogrammet gennemføres i henhold til Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 om markedsmisbrug (MAR) og Kommissionens delegerede forordning (EU) 2016/1052 af 8. marts 2016 ("Safe Harbour”-reglerne). HandelsdagAntal aktierGennemsnitlig kursBeløb Akkumuleret indtil 26/4 2024 79.600 526,89 41.940.547 mandag 29. april 2024 1.900 529,73 1.006.487 tirsdag 30. april 2024 1.000 539,39 539.390 onsdag 1. maj 2024 1.000 555,04 555.040 torsdag 2. maj 2024 1.000 556,37 556.370 fredag 3. maj 2024 1.200 556,39 667.668 I perioden 29/4 2024 - 3/5 2024 6.100 545,07 3.324.955 Samlet i perioden 4/3 2024 - 3/5 2024 85.700 528,19 45.265.502 Ved periodens udløb ejer Schouw & Co. 2.19

Schouw & Co. share buy-back programme, week 18 20246.5.2024 15:11:08 CEST | Press release

On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Trading dayNo. of sharesAverage priceAmount Accumulated until 26/4/2024 79,600 526.89 41,940,547 Monday, 29 April 2024 1,900 529.73 1,006,487 Tuesday, 30 April 2024 1,000 539.39 539,390 Wednesday, 1 May 2024 1,000 555.04 555,040 Thursday, 2 May 2024 1,000 556.37 556,370 Friday, 3 May 2024 1,200 556.39 667,668 In the period 29/4/2024 - 3/5/2024 6,100 545.07 3,324,955 Accumulated 4/3/2024 - 3/5/2024 85,700 528.19 45,265,502 Following the above transactions Schouw & Co. holds a

AKVA group ASA: Status buyback of own shares6.5.2024 14:57:37 CEST | Press release

As announced on 22 March 2024 AKVA group ASA ("AKVA group" or the "Company") has initiated repurchase of up to 200,000 of the company's own shares to be used in its share programme for employees. From 30 April through 6 May the company bought 10 855 shares at an weighted average price of NOK 65,8477. See the attached documents for detailed information about the transactions made. The company has bought a total of 57 896 shares at an weighted average price of NOK 68,3271 since 22 March. After these transactions, the company owns 288 559 treasury shares. This information is made public by the Company pursuant to the EU Market Abuse Regulation article 5, as supplemented by Commission Delegated Regulation (EU) 2016/1052 and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Dated: 6 May 2024 AKVA group ASA Web: www.akvagroup.com CONTACTS: Knut Nesse Chief Executive OfficerPhone:+47 51 77 85 00Mobile:+47 91 37 62 20E-mail:knesse@akvagrou

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®6.5.2024 14:30:00 CEST | Press release

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials.” Ampligen is currently being evaluated as

Investeringsforeningen IA Invest, Afdeling Thygesen Global Stock Selection – Endeligt resultat af tegning6.5.2024 14:23:30 CEST | pressemeddelelse

Investeringsforeningen IA Invest havde indledende tegningsperiode i afdeling Thygesen Global Stock Selection (ISIN: DK0062842134) fra den 22. april til og med den 3. maj 2024. Efter opgørelse af tegningsresultatet for afdeling Thygesen Global Stock Selection er det vurderingen, at afdelingen ikke har opnået en tilstrækkelig stor formue til at blive lanceret og optaget til handel på Nasdaq Copenhagen. Der vil som følge heraf ikke blive udstedt andele i afdeling Thygesen Global Stock Selection. Eventuelle henvendelser vedrørende denne meddelelse bedes rettet til undertegnede på telefon 38 14 66 00. Med venlig hilsen Niels Erik Eberhard Direktør

HiddenA line styled icon from Orion Icon Library.Eye